Gilead Sciences Inc. said director Nicholas Moore would retire from the board, effective as of the end of his term in May.
Moore's decision to retire was not the result of any dispute or disagreement with the company.
Gilead Sciences director to retire
A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research
2021 Year in Review: Highlighting Key Investment Banking Trends
Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings
Global M&A By the Numbers: Q3 2021
Gilead Sciences Inc. said director Nicholas Moore would retire from the board, effective as of the end of his term in May.
Moore's decision to retire was not the result of any dispute or disagreement with the company.